カレントテラピー　30-5　サンプル page 23/38

このページは カレントテラピー　30-5　サンプル の電子ブックに掲載されている23ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
化学療法と放射線療法colon cancer：results of a randomized trial. J Clin Oncol 21：2896 -2903, 20033）Lembersky BC, Wieand HS, Petrelli NJ, et al：Oral uracil andtegafur plus leucovorin compared with i....

化学療法と放射線療法colon cancer：results of a randomized trial. J Clin Oncol 21：2896 -2903, 20033）Lembersky BC, Wieand HS, Petrelli NJ, et al：Oral uracil andtegafur plus leucovorin compared with intravenous fluorouraciland leucovorin in stageⅡandⅢcarcinoma of thecolon：results from National Surgical Adjuvant Breast andBowel Project Protocol C -06. J Clin Oncol 24：2059-2064,20064）Twelves C, Wong A, Nowacki MP, et al：Capecitabine asadjuvant treatment for stageⅢcolon cancer. N Engl J Med352：2696-2704, 20055）Sakamoto J, Ohashi Y, Hamada C, et al；Meta -AnalysisGroup of the Japanese Society for Cancer of the Colon andRectum and the Meta-Analysis Group in Cancer：Efficacy oforal adjuvant therapy after resection of colorectal cancer：5 -year results from three randomized trials. J Clin Oncol22：484-492, 20046）Andre T, Boni C, Navarro M, et al：Improved overall survivalwith oxaliplatin, fluorouracil, and leucovorin as adjuvanttreatment in stageⅡorⅢcolon cancer in the MOSAICtrial. J Clin Oncol 27：3109-3116, 20097）Schmoll HJ, Cartwright T, Tabernero J, et al：PhaseⅢtrialof capecitabine plus oxaliplatin as adjuvant therapy for stageⅢcolon cancer：a planned safety analysis in 1,864 patients. JClin Oncol 25：102 -109, 20078）Van Cutsem E, Labianca R, Bodoky G, et al：RandomizedphaseⅢtrial comparing biweekly infusional fluorouracil/leucovorinalone or with irinotecan in the adjuvant treatment ofstageⅢcolon cancer：PETACC -3. J Clin Oncol 27：3117 -3125, 20099）Ychou M, Raoul JL, Douilard JY, et al：A phaseⅢrandomisedtrial of LV5FU2＋irinotecan versus LV5FU2 alonein adjuvant high -risk colon cancer（FNCLCC Accord02/FFCD9802）. Ann Oncol 20：674-680, 200910）Hamaguchi T, Shirao K, Moriya Y, et al：Final results of randomizedtrials by the National Surgical Adjuvant Study ofColorectal Cancer（NSAS -CC）. Cancer Chemother Pharmacol67：587-596, 201111）West NP, Hohenberger W, Weber K, et al：Complete mesocolicexcision with central vascular ligation produces anoncologically superior specimen compared with standard surgeryfor carcinoma of the colon. J Clin Oncol 28：272 -278,201012）Allegra CJ, Yothers G, O’Connell MJ, et al：PhaseⅢtrialassessing bevacizumab in stagesⅡandⅢcarcinoma of thecolon：results of NSABP protocol C -08. J Clin Oncol 29：11-16, 201113）de Gramont A, Van Custem E, Taberbero J, et al：AVANT：Results from a randomized, three -arm multinational phaseIII study to investigate bevacizumab with either XELOX orFOLFOX4 alone as adjuvant treatment for colon cancer.2011 Gastrointestinal Cancers Symposium. J Clin Oncol 29（suppl 4）：2011（abstr 362）14）Alberts SR, Sargent DJ, Smyrk TC, et al：Adjuvant mFOLF-OX6 with or without cetuximab（Cmab）in KRAS wild-type（WT）patients（pts）with resected stageⅢcolon cancer（CC）：Results from NCCTG Intergroup PhaseⅢTrialN0147. 2010 ASCO Annual Meeting. J Clin Oncol 28（suppl18）：2010（abstr CRA3507）15）Kato T, Ohashi Y, Nakazato H, et al：Efficacy of oral UFT asadjuvant chemotherapy to curative resection of colorectalcancer：multicenter prospective randomized trial. Langenbeck’sArch Surg 386：575-581, 200216）Aschele C, Cionini L, Lonardi S, et al：Primary tumorresponse to preoperative chemoradiation with or withoutoxaliplatin in locally advanced rectal cancer：pathologicresults of the STAR -01 randomized phaseⅢtrial. J ClinOncol 29：2773 -2780, 201117）Yothers G, O’Connell MJ, Allegra CJ, et al：Oxaliplatin asadjuvant therapy for colon cancer：updated results ofNSABP C-07 trial, including survival and subset analyses. JClin Oncol 29：3768-3774, 201118）Yothers GA, Allegra CJ, O’Connell MJ, et al：The efficacy ofoxaliplatin（Ox）when added to 5-fluorouracil/leucovorin（FU/L）in stage II colon cancer. 2011 ASCO Annual Meeting. JClin Oncol 29：2011（abstr 3507）19）Chau I, Norman AR, Cunningham D, et al：A randomisedcomparison between 6 months of bolus fluorouracil/leucovorinand 12 weeks of protracted venous infusion fluorouracilas adjuvant treatment in colorectal cancer. Ann Oncol 16：549-557, 200520）Neugut AI, Matasar M, Wang X, et al：Duration of adjuvantchemotherapy for colon cancer and survival among theelderly. J Clin Oncol 24：2368-2375, 2006Current Therapy 2012 Vol.30 No.543561